Af­ter ques­tions sur­round­ing fund­ing, Re­i­Thera re­veals high an­ti­body re­sponse for Covid-19 jab in PhII study

The Ital­ian gov­ern­ment saved drug­mak­er Re­i­Thera’s Covid-19 can­di­date ef­forts in May when it threw its sup­port and mon­ey be­hind the com­pa­ny’s own vac­cine in the mid­dle of a short­age. The move has ap­peared to pay off, as the com­pa­ny on Mon­day an­nounced that Phase II tri­al da­ta re­vealed high an­ti­body re­spons­es af­ter two dos­es.

Among pa­tients who re­ceived the first dose of vac­cine in the 917-per­son tri­al, 93% saw an an­ti­body re­sponse three weeks af­ter get­ting the jab. Fol­low­ing the sec­ond dose, that fig­ure rose to 99%, Re­i­Thera said in a re­lease. Five weeks af­ter the first vac­ci­na­tion, titers of both spike-bind­ing and SARS-CoV-2 neu­tral­iz­ing an­ti­bod­ies were com­pa­ra­ble to a ref­er­ence group of pa­tients re­cov­er­ing from Covid-19, the biotech added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER